Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
A photographer finds thousands of dinosaur footprints near Italian Winter Olympic venue- Woman gives birth on roadside after hospital allegedly sent her home: Family
- Japan deploys the military to counter a surge in bear attacks
- IDF strikes Hamas terror base in Lebanon, Health Ministry says 11 killed
- The Response to Self-improvement: Embracing a Development Outlook
- NASA releases stunning first images of Earth taken by the Artemis II astronauts
- Israel and Lebanon's Hezbollah continue to trade attacks
- The 10 Most Significant Games in History
- CDC vaccine panel votes to remove universal hepatitis B birth dose recommendation
